Week 46: Backtesting — Survivorship Bias, Look-Ahead Bias, Transaction Costs, and the Deflated Sharpe

---

1. Why This Is Important

A backtest is a story you tell yourself about a strategy. It is the most persuasive financial document in the world: a smooth equity curve, a tidy Sharpe number, a table of annual returns, all generated in a few seconds by a program you wrote yesterday. The problem is that almost every backtest is wrong, and almost every backtest is wrong in the same direction — too optimistic. Empirical work by Lopez de Prado, Bailey, and others shows that the median in-sample Sharpe of a published quant strategy roughly halves out of sample. Strategies that look like 1.5 Sharpe machines on paper deliver 0.6 in production, if anything at all. Most retail "systems" sold online deliver zero or negative excess return after realistic frictions.

You need this material for four reasons.

**You will see, build, or buy backtests for the rest of your

investing life.** Every ETF prospectus, every robo-advisor pitch, every YouTube quant influencer leads with a backtest. If you cannot reflexively spot survivorship bias, look-ahead bias, and the multiple-testing trap, you will mis-allocate capital. Alpha is rare; almost every backtest is selling you alpha. Reconcile.

The deflated Sharpe ratio is now the institutional standard.

Bailey and Lopez de Prado's 2014 paper formalised what sceptical practitioners always knew: try a thousand strategies, the best one will look great by chance. Their formula converts a raw in-sample Sharpe into one that explicitly penalises the number of trials. Modern allocators ask for it. You should compute it on your own ideas.

Transaction costs are usually the entire alpha. A

backtested edge of 4% per year, run weekly with 30 bps round-trip costs and ~50 turnovers per year, evaporates: 50 × 0.30% = 15% gross drag, swamping the edge by a factor of three. Most "discoveries" by retail systems live or die on cost modelling — which is why the slick PowerPoints all quietly omit it.

Backtesting connects to four enduring ideas. Alpha is

rare. The vol tail wags the dog — a five-year backtest without a crisis is meaningless. Markets stay irrational long enough to stop you out before reverting. And the liquid US equity universe is the one place a sceptical backtester can actually validate point-in-time data without drowning in survivor noise.

This lesson walks through the seven canonical backtest pathologies, the math of the deflated Sharpe, and a working calculator that takes your in-sample number and tells you what to actually expect out of sample.

---

2. What You Need to Know

2.1 Survivorship Bias — The Universe You Don't See

The simplest, most pernicious bias. Open any data terminal, ask for "all S&P 500 stocks since 1990, equal-weighted, monthly rebalance." Your terminal returns the current S&P 500. Lehman Brothers is missing. Bear Stearns is missing. WorldCom is missing. Sears, Kodak, Polaroid, Wachovia, Washington Mutual, Countrywide — all missing. You have backtested the strategy on a universe of survivors.

Survivorship inflates returns by roughly 1-3% per year on a US large-cap universe, more on small-caps, far more on emerging markets and on hedge fund databases that only list funds still reporting. A "long-only quality" backtest run on the survivors of 1990 looks brilliant. The same strategy run on the actual 1990 universe — including the names that bankrupted — looks mediocre.

The fix is point-in-time index membership. CRSP, Norgate, S&P's IHS-Markit, and Compustat-CapIQ all sell historical constituent files that mark which tickers were in the index on which date. Free data sources rarely have this; if you backtest with a free source, assume your top-line return is overstated by 100-300 bps.

2.2 Look-Ahead Bias — Using Tomorrow's Data Today

Look-ahead bias is when your trading rule on date t uses information that was not actually available on date t. The mechanisms are subtle.

• Restated fundamentals. Compustat shows you AAPL's FY2024

revenue as currently restated. The version available in January 2025 — before the 10-K filed in November 2025 was amended in March 2026 — was different. A backtest using current-vintage fundamentals is using future data.

• Index reconstitutions announced before effective. S&P

announces additions ~5 trading days before they take effect. A backtest that uses "in-the-index-on-date-t" with current vintage data will pick up tomorrow's adds today.

• End-of-day prices used as fill prices. Your signal fires

at 4:00 pm; you fill at the 4:00 pm close. In reality you filled the next morning, often at a worse price for momentum strategies and a better one for mean-reversion strategies. Look-ahead in fill timing flatters momentum and punishes MR.

• Earnings dates. A reported "EPS surprise" backtest that

uses the current Compustat earnings-date field will pick up some companies one day before the announcement, because the field has been retroactively normalised.

The fix is point-in-time data with as-reported timestamps, and a one-day lag rule: any signal computed on date t is acted on at the open of date t+1. Without this rule, expect 2-5% per year of phantom alpha.

2.3 Transaction-Cost Modelling — Where Most Edges Die

For US-listed liquid equities (SPY, QQQ, large caps), realistic all-in round-trip transaction costs in April 2026 are:

Universe	Round-trip cost (bps)	Notes
SPY, QQQ, top-50 mega-caps	1-3 bps	Tight spread + tiny impact
S&P 500 large-caps	5-15 bps	Avg spread ~3 bps + impact
Russell 1000 mid-caps	15-30 bps	Wider spread + slippage
Russell 2000 small-caps	30-80 bps	Spread + impact + sometimes ADV-cap
Microcap, OTC, illiquid	100-300 bps	And you may not get the size you want

These are all-in: bid-ask spread, market impact, exchange and SEC fees, plus brokerage commissions (now mostly zero for retail in the US). For institutions trading size, market impact dominates and rises roughly with the square root of (order size / ADV).

The arithmetic is brutal. A strategy with annualised gross alpha $\alpha$ and turnover $\tau$ (round-trips per year) and round-trip cost $c$ delivers net alpha:

$$ \alpha_{\text{net}} = \alpha_{\text{gross}} - \tau \cdot c $$

A 4% gross alpha at:

• $\tau = 0.5$ (annual rebalance), $c = 10$ bps → net = 3.95% — costs negligible.
• $\tau = 6$ (monthly), $c = 10$ bps → net = 3.40% — modest drag.
• $\tau = 50$ (weekly), $c = 30$ bps → net = -11% — entire alpha and then some lost.
• $\tau = 252$ (daily), $c = 30$ bps → net = -71.6% — strategy is a furnace.

This is why daily and intraday strategies rarely survive in illiquid universes: even tiny gross edges are eaten alive by turnover × cost. The chart in §2.5 makes this concrete.

The diagonal lines fan out from the same starting point on the left. By the time you reach 30 bps round-trip — typical for small-cap US — the daily strategy has lost all of its alpha and then some. This is why most published "high-frequency" retail systems are pure storytelling: they look great in zero-cost simulations and are catastrophic with realistic friction.

2.4 The Multiple-Testing Problem — 1000 Random Strategies

Here is the single most under-appreciated fact in retail quant: **if you try enough strategies, some will look great by chance**. This is not a hypothesis. It is arithmetic.

Suppose you simulate 1000 strategies, each with **zero true edge** — pure noise. Each generates an in-sample annualised Sharpe estimate. Because Sharpe is a noisy estimator (with finite sample size), the distribution of those 1000 estimates is wide. For a one-year window of daily returns, the standard error of the estimated annualised Sharpe is roughly 1.0. So out of 1000 random strategies you should expect, by pure chance:

• ~25 with Sharpe > 2.0 (one-tail probability ~ 2.5%).
• ~160 with Sharpe > 1.0 (~ 16%).
• ~3 with Sharpe > 3.0 (~ 0.3%).

Every one of these is pure noise. Yet a researcher who ran a 1000-strategy grid search and only reports the best would proudly publish a "Sharpe 3 strategy" with a t-stat of 3, and the reviewer who does not adjust for the trial count will believe it.

The vertical lines are at Sharpe = 2 and Sharpe = 3. Every bar to the right of those lines is a strategy with **literally zero alpha** that nonetheless tested above the conventional thresholds.

2.5 The Deflated Sharpe Ratio — Bailey & Lopez de Prado

Bailey, Borwein, Lopez de Prado, and Zhu (2014) wrote down a formal correction. The deflated Sharpe ratio (DSR) starts from the observed in-sample Sharpe $\widehat{SR}$, subtracts the expected maximum-of-N null Sharpe, and divides by the distribution-aware standard error of the Sharpe estimator:

$$ \widehat{SR}_0 \approx \sqrt{\frac{2 \ln N}{T}} \quad \text{(expected max under null, large N)} $$

where $N$ is the number of strategy variants tried and $T$ is the sample length in periods.

$$ \text{DSR} = \Phi\!\left(\frac{(\widehat{SR} - \widehat{SR}_0)\sqrt{T-1}}{\sqrt{1 - \gamma_3 \widehat{SR} + \frac{\gamma_4 - 1}{4}\widehat{SR}^2}}\right) $$

Here $\gamma_3$ is skewness and $\gamma_4$ is kurtosis of returns; $\Phi$ is the standard-normal CDF. Read the output as a probability: DSR is the chance that the strategy's true Sharpe is above the multiple-testing-adjusted null. A DSR of 0.95 means 95% confident the strategy is real; 0.50 means a coin flip; 0.30 is "probably noise."

The intuition is simple even if the formula is not: **reporting the best of N tries is like running a one-tailed test at significance level 1/N**. To clear that bar, your raw Sharpe has to beat $\sqrt{2 \ln N / T}$ — and for N = 1000 trials over T = 5 years of daily data, that haircut is roughly $\sqrt{2 \times 6.91 / 1260} \approx 0.10$ on a daily SR, or about 1.66 on an annualised SR. So a researcher reporting Sharpe 2.0 from a 1000-strategy search has, after deflation, an effective Sharpe of roughly 0.34 — barely better than the bond market.

2.6 Walk-Forward Analysis — The Gold Standard

The honest way to validate a strategy is walk-forward: fit parameters on a rolling window, test on the immediately subsequent out-of-sample window, then roll forward. For example: fit on 2010-2014, test 2015; fit on 2011-2015, test 2016; and so on. The concatenation of the test-period returns is your true out-of-sample track record.

Walk-forward kills three birds:

• Look-ahead. You can only fit on data older than the test

window, by construction.

• Overfitting. If your strategy needs 12 parameters to look

good in-sample, the rolling refits will produce wildly different parameter sets each window — a tell that the parameters are not capturing a real signal.

• Regime drift. A strategy that worked 1995-2005 but failed

2015-2025 will show in the walk-forward equity curve as a clean break. A naïve full-sample backtest hides that break inside the averages.

A strategy whose walk-forward Sharpe is less than half of its full-sample in-sample Sharpe is overfit. Most published retail systems fail this test on inspection.

2.7 Regime-Shift Robustness

Even after deflation, walk-forward, and proper costs, one final question remains: does the strategy work in different regimes? A momentum strategy that backtests beautifully on 2010-2021 (one long QE-driven uptrend) is not the same as one that backtests across 1929-32, 1973-74, 2000-02, 2008, and 2020 stress windows.

A useful discipline: split your sample into the canonical regime buckets (Week 10's framework) and report Sharpe, drawdown, and hit-rate within each regime. A strategy that works in three of four regimes and fails in one is potentially deployable with a regime overlay. A strategy that only works in one regime is a beta exposure dressed up as alpha. The 1980-2020 regime was anomalous; do not let your sample window inherit its flattering arithmetic.

The interactive at the end of this lesson lets you drag five sliders — in-sample Sharpe, years of backtest, number of strategies tried, round-trip cost, and trades per year — and watch four numbers update live: deflated Sharpe (multiple-testing penalty), out-of-sample Sharpe estimate, Sharpe-after-costs, and the probability the strategy is real. Most "great" backtests collapse instantly under realistic settings.

---

3. Common Misconceptions

"My backtest looks great, so the strategy works." Your

backtest is a best-case simulation under your particular choices of data, costs, and timing. The realised performance is almost always worse — and alpha is rare, so the prior on any backtest is that it is overstated.

"Survivorship bias is a problem only for small-caps." It

is a problem everywhere. Lehman, Bear, WorldCom, Enron, GE removed from the Dow — all large-cap. The bias is universal; it is just larger in noisier universes.

"I used adjusted prices, so I'm fine." Split- and

dividend-adjusted prices fix one issue (corporate-action distortion) but tell you nothing about whether the ticker was in the relevant universe at the historical date.

**"Transaction costs are negligible for retail because

commissions are zero."** Zero commission ≠ zero cost. Spread plus market impact still costs you 5-30 bps round-trip on most US equities, and far more on small-caps. The "commission-free" branding is marketing.

"I tested in-sample and out-of-sample, so I'm fine." A

single in/out split is barely better than no split when you chose the split point after seeing the data. Walk-forward is the standard.

"P-value below 0.05 means the strategy is real." Not if

you tried more than 20 variants. Multiple-testing correction (Bonferroni, FDR, or DSR) is mandatory.

**"Deflated Sharpe is too conservative — it kills good

strategies."* It kills most* strategies, and that is correct. Alpha is rare — the deflation is just that fact in formula form.

"Higher in-sample Sharpe is better." Higher in-sample

Sharpe with fixed sample size and fixed turnover is better, yes. Higher in-sample Sharpe coming from a larger search space is worse — because you tried more.

"Walk-forward eliminates overfitting." It reduces it; it

does not eliminate it. If the underlying strategy class is overfit (e.g., 12 parameters), walk-forward parameters will still flap around and out-of-sample performance will still degrade, just less catastrophically.

"Regime-robust strategies are the only good ones." Some

perfectly good strategies work only in specific regimes (trend-following in trending markets, value in mean-reverting ones). The honest play is to acknowledge the regime and size accordingly, not to pretend the strategy is all-weather.

---

4. Q&A Section

Q1. How many strategy variants do I have to declare? A1. Every variation tried — across asset universes, parameter grids, signal definitions, and rebalance frequencies. If you ran a 5×5×4 grid search, $N = 100$. Including the variants you tried and discarded "because they didn't look good" is critical; omitting them is the heart of p-hacking.

Q2. What's a realistic out-of-sample haircut on the in-sample Sharpe? A2. The literature finds the median OOS Sharpe of published quant strategies is roughly 50% of the in-sample Sharpe, and the worst quartile delivers zero or negative. A reasonable working assumption: $\widehat{SR}_{\text{OOS}} \approx 0.5 \times \widehat{SR}_{\text{IS}}$ before costs.

Q3. What round-trip cost should I assume for a Russell 2000 strategy? A3. 30-50 bps for institutional sizing on liquid small-caps. Up to 80-100 bps for the bottom decile of small-caps where ADV is low. Retail traders moving small notional can sometimes do 15-25 bps but cannot scale it.

**Q4. My in-sample Sharpe is 1.5 over 5 years and I tried 200 variants. Is that worth deploying?** A4. Run the deflated Sharpe. With $T \approx 1260$ days and $N = 200$, $\widehat{SR}_0 \approx \sqrt{2 \ln 200 / 1260} \approx 0.092$ on a daily basis, or about 1.46 annualised. So your 1.5 IS Sharpe is essentially the multiple-testing null — DSR will be near 50%. That is a coin flip, not a strategy.

Q5. Why is daily-frequency a graveyard for retail quants? A5. Daily turnover at 252 round-trips per year times even 10 bps cost is 25.2% annualised drag. You need a 25%+ gross edge before you net anything. Arithmetic plus the rarity of alpha: those edges effectively do not exist for retail.

**Q6. How do I get point-in-time fundamental data without paying for Compustat?** A6. Imperfectly. Free EDGAR scraping gets you as-filed financials with proper timestamps, but reconstructing the full universe is painful. Quandl (now Nasdaq Data Link) sells some point-in-time slices at retail prices. For most retail purposes, lag your fundamental data by 90 days as a crude correction.

Q7. Does walk-forward preserve transaction-cost realism? A7. Yes — and it should. The cost model applies inside each walk-forward step exactly as it would in live trading. If anything, walk-forward exposes cost-sensitivity better than full-sample backtests because it reveals turnover changes across parameter refits.

**Q8. My strategy works in bull markets and fails in bear markets. Is it deployable?** A8. Maybe — with a regime overlay. Identify the trigger (e.g., 200-day moving average, VIX threshold) that turns it on and off, and incorporate that switch into the backtest. If the strategy is profitable only with the regime overlay, your "alpha" is partly the overlay's alpha. Be honest about attribution.

**Q9. Should I use bootstrap or block-bootstrap to estimate Sharpe confidence intervals?** A9. Block bootstrap (with block length matched to the auto-correlation of the strategy's returns) is the right tool for serially correlated strategies — most of them. Naïve i.i.d. bootstrap understates the variance.

Q10. What's the simplest defensible backtest workflow? A10. Five steps. (1) Define the strategy in one paragraph before looking at data. (2) Use point-in-time data with a one-day signal-to-execution lag. (3) Apply realistic costs based on the universe. (4) Walk-forward at quarterly or yearly re-fits. (5) Compute deflated Sharpe with honest $N$. If the deflated Sharpe is below ~0.7, do not deploy.

*Q11. Can survivor bias ever flatter a strategy less* than expected?** A11. Rarely, in highly distressed periods where the strategy was specifically betting on the survivors (e.g., long-quality through 2008). Even then, the bias usually rounds in favour of the backtest. Default assumption: survivorship adds 100-300 bps/year.

**Q12. How does Horace size a strategy after passing all of these tests?** A12. Barbell sizing at the L4 sleeve level. A strategy that deflates to a Sharpe of ~1 OOS, with realistic costs and a multi-regime sample, gets a small slice of the *opportunity sleeve* — usually 1-3% of total wealth. If it works, fine. If it does not, the 90%+ core is unaffected. Backtests are not permission to bet large; they are permission to bet some.